REGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugsREGULATORYRFK Jr.: 14 peptides returning to Category 1 — FDA advisory committee July 2026UPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORYBPC-157, TB-500, thymosin alpha-1, CJC-1295, ipamorelin: expected Category 1 reclassification pendingFDAFDA advisory committee meetings scheduled: late July 2026RESEARCHA Phase 2 Study of Vosoritide in Children With Idiopathic Short Stature [NCT06382155]RESEARCHMetabolic Effects of Angiotensin-(1-7) [NCT02646475]RESEARCHEvaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder [NCT06651177]RESEARCHMulti-Site Trial of Tirzepatide for Smoking Cessation [NCT07602699]RESEARCHA Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide [NCT06897475]RESEARCHTranslational Health Research Into Vascular and Neurocognitive Effects of Weight Loss [NCT07592546]RESEARCHTirzepatide in the Treatment of Endometrial Cancer [NCT07605247]RESEARCHA Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan [NCT06635057]RESEARCHA Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) [NCT07165028]NEWSOorja, run by Acceleron veterans, launches to make new fibrosis drugs

For research purposes only. Full disclaimer →

Protocols
13

IGF-1 LR3 — Comprehensive Protocol Review

Rowan Huang·about 1 month ago
Completing my IGF-1 LR3 protocol review after running it for the full planned duration. This is a comprehensive look back at what worked, what did not, and what I would change for next time. Overall assessment: positive results that justified the commitment. The effects built gradually over the first 4-5 weeks and then maintained throughout the remainder. No significant side effects after the initial adjustment period. What worked well: consistent timing, meticulous tracking, and patience. The temptation to increase dose when progress feels slow is real, but sticking to the plan paid off. The benefits compounded over time in a way that was not obvious week-to-week but very clear when comparing month 1 to month 3. What I would change: I would front-load the tracking setup before starting. Having a clear baseline with bloodwork, body composition measurements, and a week of subjective scoring before the first dose would have made the early weeks of data more useful. Recommendation: if you are considering IGF-1 LR3, give it a proper trial of at least 8 weeks at a consistent dose before making any judgments. The short-term experimenters miss the real benefits.

Comments (4)

Merit GallagherDEMO·about 1 month ago

One thing I wish more IGF-1 LR3 discussions covered is the discontinuation experience. What happens when you stop? In my case, the benefits gradually faded over about 3-4 weeks after stopping. Sleep was the first thing to return to baseline. Recovery improvements lasted a bit longer. Worth knowing for planning protocol duration.

3
Jesse BurnsDEMO·about 1 month ago

Great point about bloodwork. I ran comprehensive panels at baseline, 6 weeks, and 12 weeks during my IGF-1 LR3 protocol. The most informative markers for me were inflammatory markers and IGF-1 levels. Would strongly recommend anyone running IGF-1 LR3 to invest in proper monitoring.

4
Flint BellDEMO·about 1 month ago

The timeline you describe is spot on with my IGF-1 LR3 experience. I also want to emphasize the importance of injection technique. When I switched from 30-gauge to 29-gauge needles and slowed my injection speed, the site irritation essentially disappeared. Small details make a big difference in compliance.

5
Dakota AshworthDEMO·about 1 month ago

Following up on my earlier comment about IGF-1 LR3. I am now 4 weeks past the end of my protocol and wanted to report that about 60 percent of the benefits seem to have persisted. Sleep is still better than baseline, recovery is somewhere between pre-protocol and on-protocol levels. Encouraging for the sustainability question.

6

Sign in to comment.